Project data
Funding Entity: European Commission
Call: HORIZON-HLTH-2022-TOOL-11
Coordinator:101095436 (Italy)
UNISI Principal Investigator: Andrea Fagiolini
Department: Molecular and Developmental Medicine
Start date: 1 December 2022 – End date: 1 May 2027
Description
Major depressive disorders (MDD) affect 280 million people worldwide. Several antidepressants exist. However, very few patients (less than 6 %) benefit from therapeutic methods. The EU-funded OPADE project will identify critical biomarkers that support the decision-making process of healthcare providers by focusing on the microbiota–brain axis, which plays a central role in mental health and MDD. By studying genetics, epigenetics, microbiomes and inflammatory networks to establish patient profiles, the project will predict and optimise antidepressant efficacy. It will also investigate the possible correlation between neuroinflammatory indices, target indicators of the microbiome, metabolomics, immune profiling as well as epigenomic and enzymatic algorithms. The project will use the results and analysis to train the artificial intelligence and machine learning predictive tool.
Source: Cordis
This project has received funding from the European Union’s Horizon 2020 programme under GA No 101095436